Company news
Osr Holdings, Inc. (NASDAQ:OSRH) news
Osr Holdings, Inc. news releases on 6ix. Latest, Aug 21, 2026: OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
Press releases & updates
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
August 21, 2026
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
August 19, 2026
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
August 19, 2026
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
August 7, 2026
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
August 3, 2026
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
July 31, 2026
OSR Health, A Message From the CEO
July 13, 2026
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
June 25, 2026
OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do
June 22, 2026
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
May 27, 2026
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
April 30, 2026
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
April 29, 2026
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
April 8, 2026
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026
March 30, 2026
OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
March 22, 2026
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
March 19, 2026
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
March 19, 2026
OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum
March 4, 2026
CEO Statement to Shareholders
February 2, 2026
OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
January 27, 2026
Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch
January 22, 2026
Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
January 16, 2026
Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings
December 19, 2025
Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months
December 2, 2025
OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025
December 1, 2025
OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion
November 14, 2025
OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study
November 6, 2025
OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care
October 14, 2025
OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity
September 9, 2025
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
August 1, 2025
OSR Holdings Provides Transparency Update on Equity Financing Instruments
July 31, 2025
OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure
July 30, 2025
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
July 24, 2025
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
July 15, 2025
OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG
July 7, 2025
OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token
May 21, 2025
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
May 2, 2025
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
April 3, 2025
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
March 25, 2025
OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination
February 13, 2025
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
April 21, 2024
OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.
November 15, 2023